Strategic partnering to enable cell therapy commercialization

Cell & Gene Therapy Insights 2022; 8(9), 1187–1193

DOI: 10.18609/cgti.2022.176

Published: 2 October 2022
Expert Insight

As emerging cell therapies move towards the commercialization phase, focus has been placed on establishing scalable and reproducible manufacturing processes and incorporating innovations to streamline cell therapy manufacturing. This article will discuss how strategic partnering between biotech and pharma companies can facilitate the challenging transition of moving therapies through the commercialization pipeline.